A comprehensive collection of research articles, scientific papers, and relevant publications produced by the Breast Health Working Group International, providing valuable insights and contributing to the global knowledge base in the field of breast health and breast cancer research. 1.   18F-FDG PET/CT in Early Stage Breast Cancer Comes with Financial Burden. https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2024/julyaugust-2024-volume-109-issue-7/18f-fdg-petct-in-early-stage-breast-cancer-comes-with-financial-burden/. Atilla Soran, MD, MPH, FACS, Mehmet Ali Nazlı, MD, Osman Toktas, MD, and Serdar Ozbas, MD, FEBS 2.   Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-instutional Registry Study-IMET, Protocol MF 14-02. https://pubmed.ncbi.nlm.nih.gov/35876920/ Soran et al. Annals of Surgical Oncology volume 29, pages6327–6336 (2022). The surgical resection or ablative interventions may contribute to the survival of breast cancer patients with a limited number and operable metachronous hepatic/pulmonary metastases. 3.   Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer. https://pubmed.ncbi.nlm.nih.gov/35820106/. Soran et al. Correspondence. Journal of Clinical Oncology 2022 40:33, 3897-3898 https://doi.org/10.1200/JCO.22.00802. In light of this discussion, we shared our concerns that the LRT does not provide a survival advantage in dn stage IV BC. 4.   The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study. https://pubmed.ncbi.nlm.nih.gov/33532878/ Soran et al. Ann Surg Oncol​. 2021 Sep;28(9):5048-5057. doi: 10.1245/s10434-021-09621-8. Epub 2021 Feb 2. The LRT prolonged overall survival and SPFS and decrease locoregional recurrence in a median 3 year follow up. Timing of primary breast surgery either at diagnosis or after ST provided a similar survival benefit compare with ST alone in de novo stage IV BOM BC patients.  5.   Correspondence to ‘’ Locoregional therapy in de novo metastatic breast cancer: Systematic review and meta-analysis, written by Reinhorn D et al. https://pubmed.ncbi.nlm.nih.gov/34654601/  In The Breast Journal 58 (2021) 173-181’’. Soran et al. In The Breast Journal 58 (2021) 173e181”, The Breast, https://doi.org/10.1016/j.breast.2021.10.002. There is a group of patients, such as having low tumor burden and bone metastatic group, has a survival benefit when cautiously evaluated for primary breast surgery in de novo stage IV BC. 6.   The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q. https://pubmed.ncbi.nlm.nih.gov/33242163/.     Soran et al. Supportive Care in Cancer, Springer 2020, DOI 10.1007/s00520-020-05905-z. Patient who had LRT has similar physical and mental health outcomes compared to ST only in a cohort of patients who lived longer than three years. 7.   A Novel First-Line Treatment Alternative for Noncomplicated Idiopathic Granulomatous Mastitis: Combined Intralesional Steroid Injection with Topical Steroid Administration. https://pubmed.ncbi.nlm.nih.gov/34012373/ Toktas et al. Breast Care 2021;16:181–187 DOI: 10.1159/000507951. The comparison between the efficacy of combined intralesional  steroid injection with topical steroid administration to systemic streoid therapy in the treatment of noncomplicated IGM. 8.   Loco-Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2018 Trial. https://pubmed.ncbi.nlm.nih.gov/32656512/ Soran et al.Eur J Breast Health 2020; 16(3): 158-159DOI: 10.5152/ejbh.2020.080620. It is important to achieve local control in oligometastatic cases, especially in patients with bone only metastases. In addition, surgical removal of the primary tumor is important to prevent local spread to the pleura and pericardium. 9.   Are we close to the end of primary tumor resection discussion for de novo stage IV BC? https://pubmed.ncbi.nlm.nih.gov/30528045/  A.Soran, European Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.ejso.2018.09.022. LRT should be considered in selected cases; oncologists must consider age, performance status, comorbidities, tumor type, and metastatic disease burden while discussing LRT with patients. 10.                Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. https://pubmed.ncbi.nlm.nih.gov/29777404/ Soran et al. Ann Surg Oncol. 2018 Oct;25(11):3141-3149. doi: 10.1245/s10434-018-6494-6.  The first randomized controlled trial in denovo metastatic breast cancer. 11.                Factors related to recurrence of idiopathic granulomatous mastitis what do we learn from a multicentre study? https://pubmed.ncbi.nlm.nih.gov/29777404/  Uysal et al. doi: 10.1111/ans.14115. Having a history of pregnancy, breastfeeding, breast infection, and smoking increases the risk of IGM recurrence. However, the treatments examined in this study did not affect the recurrence of IGM. 12.                ASO Author Reflections: Is Intensifying Loco-Regional treatment In the Early Course of De Novo Stage IV Breast Cancer Reasonable? https://pubmed.ncbi.nlm.nih.gov/30357577/  The evolution of LRT to BC from past to future. A.Soran, A brief invited commentary on the article. 13.                Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. https://pubmed.ncbi.nlm.nih.gov/19535217/ Gur et al.2009 Elsevier, doi:10.1016/j.ejso.2009.05.007. Various nomograms were assessed to detect non-sentinel lymph node metastasis (NSLNM) in breast cancer patients with positive sentinel lymph nodes (SLN).